Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas
Reuters
Oct 20
Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas
Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate $(ADC)$, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.